Ventilator-associated pneumonia (VAP) occurs frequently in mechanically ventilated patients and has a high mortality rate. To date, there is no consensus for the diagnosis of VAP. Effective reduction in VAP-inducedmortality requires amultifaceted approach to include assessment of individual risks for VAP, implementation of effective ventilator handling procedures, routine use of VAP prevention strategies, appropriate use and interpretation of invasive and noninvasive diagnostic tests, and early broad spectrum antibiotic coverage with narrowing of coverage and cessation of therapy based on clinical improvement. Pharmacokinetic and pharmacodynamic principlesmust be used in designingempiric antibiotic regimens. Because an inappropriate empiric regimen in VAP has been associated with increasedmortality, it is imperative to maintain intensive care unit–specific epidemiologic data.
Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867-903.
2.
Centers for Disease Control and Prevention. Guidelines for prevention of nosocomial pneumonia. MMWR Morb Mortal Wkly Rep. 1997;46(RR-1):1-79.
3.
Marino PL. The ICU Book. 2nd ed.Baltimore, Md: Williams & Wilkins; 1998.
4.
Cunnion KM, Weber DJ, Broadhead WE, Hanson LC, Pieper CF, RutalaWA. Risk factors for nosocomial pneumonia: comparing adult critical care populations. Am J Respir Crit Care Med. 1996;153:158-162.
5.
Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large U.S. database. Chest. 2002;122:2115-2121.
6.
Pawar M,Mehta Y, Khurana P, Chaudhary A, Kulkarni V, Trehan N.Ventilator-associated pneumonia: incidence, risk factors, outcome, and microbiology. J Cardiothorac Vasc Anesth. 2003; 17:22-28.
7.
Apostolopoulou E, Bakakos P, Katostaras T, Gregorakos L. Incidence and risk factors for ventilator-associated pneumonia in 4 multidisciplinary intensive care units in Athens, Greece. Respir Care. 2003;48:681-688.
8.
Shorr AF,Duh MS,Kelly KM,Kollef MH. Red blood cell transfusion and ventilator-associated pneumonia: a potential link?Crit Care Med.2004;32:666-674.
9.
Rello J, Diaz E, Roque M, Valles J. Risk factors for developing pneumoniawithin 48 hours of intubation.Am J Respir Crit Care Med.1999;159:1742-1746.
10.
Flanagan PG, Findlay GP, Magee JT, Ionescu A, Barnes RA, Smithies M. The diagnosis of ventilator-associated pneumonia using non-bronchoscopic, non-directed lung lavages. Intensive Care Med.2000;26:20-30.
11.
Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med.1995;152(6 pt 1):1982- 1991.
12.
Mueller EW, Wood GC, Kelley MS, Boucher BA, Fabian TC, Croce MA. The predictive value of preliminary bacterial colony counts from bronchoalveolar lavage in critically ill trauma patients. Am Surg. 2003;69:749-755.
13.
Rello J, Paiva JA,Baraibar J, et al. International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest.2001;120:955-970.
14.
Miller PR,Meredith JW, ChangMC. Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage. J Trauma.2003;55:263-267.
15.
Croce MA, Fabian TC, Mueller EW, et al. The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma. 2004;56:931-934.
16.
Pugin J. Clinical signs and scores for the diagnosis of ventilatorassociated pneumonia. Minerva Anestesiol. 2002;68:261-265.
17.
Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. Thorax. 1999;54: 867-873.
18.
Fartoukh M,Maitre B,Honore S, Cerf C, Zahar JR, Brun-Buisson C. Diagnosing pneumonia during mechanical ventilation: the clinical pulmonary infection score revisited. Am J Respir Crit Care Med.2003;168:173-179.
19.
Schurink CA, Van Nieuwenhoven CA, Jacobs JA, et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med.2004;30:217-224.
20.
Luyt CE, Chastre J, Fagon JY. Value of the clinical pulmonary infection score for the identification and management of ventilatorassociated pneumonia. Intensive Care Med.2004;30:844-852.
21.
Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med.2003;31:676-682.
22.
Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med.1999;27:887-892.
23.
Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea TM. A time-dependent analysis of intensive care unit pneumonia in trauma patients. J Trauma. 2004;56:296-301.
24.
Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement from the American Thoracic Society. AmJ Respir Crit Care Med. 1995;153:1711-1725.
25.
Baughman RP, Kerr MA. Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis. J Intensive CareMed. 2003;18:269-274.
26.
Chastre J, WolffM, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA. 2003;290:2588-2598.
27.
Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004;125:1791-1799.
28.
Brun-Buisson C, Sollet J, Schweich H, Briere S, Petit C.Treatment of ventilator-associated pneumonia with piperacillintazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis. 1998;26:346-354.
29.
Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenemcilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003;47:3442-3447.
30.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittell M.Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparisonwith imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-1118.
31.
Baldwin DR, Honeybourne D, Wise R.Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother. 1992;36(6):1176-1180.
32.
Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28:936-942.
33.
Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;1998:531-539.
34.
Lamer C, De Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37:281-286.
35.
Centers for Disease Control and Prevention. Staphylococcus aureusresistant to vancomycin—United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565-567.
36.
Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococus aureus—Pennsylvania, 2002. MMWRMorbMortal Wkly Rep. 2002;51:902-902.
37.
Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus—New York, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:322-323.
38.
Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes fromEnterococcus faecalisNCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992;93:195-198.
39.
Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 1995;44(RR-12): 1-13.
40.
Conte JE, Golden JA, Kipps J, Zurlinden E.Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46:1475-1480.
41.
Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG, and the Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, doubleblind, multicenter study. Clin Infect Dis. 2001;32:402-412.
42.
Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980-992.
43.
Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, KollefMH. Analysis of two double-blind studies of patientwith methcillin-resistant Staphylococcus aureusnosocomial pneumonia. Chest. 2003;124:1789-1797.
44.
Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureusventilator-associated pneumonia. AmJ Respir Crit Care Med. 2004;170:786-792.
45.
Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-208.
46.
KollefMH. The prevention of ventilator associated pneumonia. N Engl J Med. 1999;340:627-634.
47.
Zeitoun SS, de BarrosAL, Diccini S.Aprospective, randomized study of ventilator-associated pneumonia in patients using a closed vs. open suction system. J Clin Nurs. 2003;12:484-489.
48.
RabitschW, KostlerWJ, FiebigerW, et al. Closed suctioning system reduces cross-contamination between bronchial system and gastric juices. Anesth Analg. 2004;99:886-892.
49.
Hess DR, Kallstrom TJ, Mottram CD, Myers TR, Sorenson HM, VinesDL. Care of the ventilator circuit and its relation to ventilatorassociated pneumonia. Respir Care. 2003;48:869-879.
50.
Cook DJ, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: ameta-analysis. AmJMed. 1991;91:519-527.
51.
Tryba M. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med. 1991;19:942-949.
52.
Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA. 1996;275:308-314.
53.
Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med. 1998;338:791-797.
54.
Collard HR, Saint S, Matthay MA. Prevention of ventilatorassociated pneumonia: an evidence-based systematic review. Ann Intern Med. 2003;138:494-501.
55.
Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med. 2004;32:1396-1405.
56.
Kress JP, Pohlman AS, O'ConnorMF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342:1471-1477.
57.
Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP. Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med. 2004;32:1272-1276.
58.
Kollef MH. The role of selective digestive tract decontamination on mortality and respiratory tract infections: a meta-analysis. Chest. 1994;105:1101-1108.
59.
Heyland DK, Cook DJ, Jaeschke R, Griffith L, Lee HN, Guyatt GH. Selective decontamination of the digestive tract. An overview. Chest. 1994;105:1221-1229.
60.
de Jonge E, SchultzMJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet. 2003;362:1011-1016.
61.
Rodriguez-Roldan JM, Altuna-Cuesta A, Lopez A, et al. Prevention of nosocomial lung infection in ventilated patients: use of an antimicrobial pharyngeal nonabsorbable paste. Crit Care Med. 1990;18:1239-1242.
Bergmans DC, BontenMJ, Gaillard CA, Paling JC, Van Der Geest S, Van Tiel FH. Prevention of ventilator-associated pneumonia by oral decontamination. Am J Respir Crit Care Med. 2001;164:382-388.
64.
Grap MJ, Munro CL, Elswick RK, Sessler CN, Ward KR. Duration of action of a single, early oral application of chlorhexidine on oral microbial flora in mechanically ventilated patients: a pilot study. N Engl J Med. 2004;340:627-634.
65.
Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO. Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Am J Crit Care. 2002;11:567-570.
66.
Dodek P, Keenan S, Cook D, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med. 2004;141:305-313.
67.
Dries DJ, McGonigalMD, MalianMS, Bor BJ, Sullivan C.Protocoldriven ventilator weaning reduces use of mechanical ventilation, the rate of early intubation, and ventilator-associated pneumonia. J Trauma. 2004;56943-952.
